(Q45115174)

9 December 2017

1 reference

title

Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. (English)

1 reference

9 December 2017

1 reference

Usuki E

1

1 reference

9 December 2017

Van der Schyf CJ

series ordinal

2

1 reference

9 December 2017

Castagnoli N Jr

series ordinal

3

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

9 December 2017

published in

Drug Metabolism Reviews

1 reference

9 December 2017

volume

30

1 reference

9 December 2017

issue

4

1 reference

9 December 2017

page(s)

809-826

1 reference

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Pharmacokinetics of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Research and society: a relationship with two faces

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Tardive dyskinesia. A discontinuation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Neuroleptic medications inhibit complex I of the electron transport chain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Cytochrome P-450 monooxygenases and interactions of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Membrane preconcentration-capillary electrophoresis-mass spectrometry in the analysis of biologically derived metabolites and biopolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Comparison of two high-performance liquid chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Stereospecific reduction of haloperidol in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Oxidative polymorphism of debrisoquine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

The MPTP-treated mouse as a model of parkinsonism: how good is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Formation of pyridinium species of haloperidol in human liver and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Hyperactive behavioural effects induced by intranigral infusion of a pyridinium metabolite of haloperidol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Morphochemical changes in brain structures in the course of chronic haloperidol treatment and the correction of these changes with tuftsin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Tardive dyskinesia: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03602539808996331

10.3109/03602539808996331

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference